share_log

Earnings Call Summary | Trevi Therapeutics(TRVI.US) Q4 2023 Earnings Conference

Futu News ·  Mar 21 06:24  · Conference Call

The following is a summary of the Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • No financial performance details provided for this period.

Business Progress:

  • Trevi initiated three clinical trials towards the end of 2023.

  • Trevi is progressing with the Phase 2a RIVER trial for Refractory Chronic Cough, a condition currently lacking approved therapeutic solutions.

  • The drug under test, Haduvio, shows potential for treating patients across different cough frequencies.

  • A Phase 2b study for chronic cough in IPS was also initiated at the end of 2023.

  • Progress is seen in the Human Abuse Potential (HAP) study, with more than half the target demographic already enrolled.

  • Topline data from the chronic cough and HAP studies are anticipated to be released in the second half of this year.

  • Significant updates are anticipated after end-of-Phase 2 meetings are initiated.

More details: Trevi Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment